Abstract
Post-operative atrial fibrillation (AF) occurs in up to 40% of cardiac surgery patients and represents the most common post-operative arrhythmic complication. Post-operative AF is associated with impaired cardiac hemodynamics, increased incidence of serious complications (e.g. heart failure, stroke), prolonged hospitalization and increased healthcare costs. Therefore, treatment of post-operative AF would decrease health-care costs during hospitalization and improve the prognosis of patients following cardiovascular surgery. Current consensus guidelines recommend -blockers, amiodarone and sotalol for post-operative AF prophylaxis. However, new pharmacological agents have been associated with a reduction in post-operative AF frequency, including inhibition of the renin angiotensin aldosterone system (RAAS) using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), statins, antioxidant agents, magnesium supplementation and antiarrhythmic drugs. The aim of this review is to analyse and determine the efficiency of existing therapies in the reduction of post-operative AF development.
Keywords: Post-operative atrial fibrillation, inflammation, remodeling, -blockers, sotalol, amiodarone, renin-angiotensinaldosterone system modulators, statins
Mini-Reviews in Medicinal Chemistry
Title:Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery
Volume: 12 Issue: 13
Author(s): Esteban Orenes-Pinero, Silvia Montoro-Garcia, Amitava Banerjee, Mariano Valdes, Gregory YH Lip and Francisco Marin
Affiliation:
Keywords: Post-operative atrial fibrillation, inflammation, remodeling, -blockers, sotalol, amiodarone, renin-angiotensinaldosterone system modulators, statins
Abstract: Post-operative atrial fibrillation (AF) occurs in up to 40% of cardiac surgery patients and represents the most common post-operative arrhythmic complication. Post-operative AF is associated with impaired cardiac hemodynamics, increased incidence of serious complications (e.g. heart failure, stroke), prolonged hospitalization and increased healthcare costs. Therefore, treatment of post-operative AF would decrease health-care costs during hospitalization and improve the prognosis of patients following cardiovascular surgery. Current consensus guidelines recommend -blockers, amiodarone and sotalol for post-operative AF prophylaxis. However, new pharmacological agents have been associated with a reduction in post-operative AF frequency, including inhibition of the renin angiotensin aldosterone system (RAAS) using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), statins, antioxidant agents, magnesium supplementation and antiarrhythmic drugs. The aim of this review is to analyse and determine the efficiency of existing therapies in the reduction of post-operative AF development.
Export Options
About this article
Cite this article as:
Orenes-Pinero Esteban, Montoro-Garcia Silvia, Banerjee Amitava, Valdes Mariano, YH Lip Gregory and Marin Francisco, Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery, Mini-Reviews in Medicinal Chemistry 2012; 12 (13) . https://dx.doi.org/10.2174/13895575112091419
DOI https://dx.doi.org/10.2174/13895575112091419 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) ATP Hydrolysis-Dependent Multidrug Efflux Transporter: MDR1 / Pglycoprotein
Current Drug Metabolism Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Current Pharmaceutical Design Polyphenols Regulate Endothelial Functions and Reduce the Risk of Cardiovascular Disease
Current Pharmaceutical Design The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Preconditioning and Shear Stress in the Microcirculation in Ischemia-Reperfusion Injury
Current Cardiology Reviews Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews p53: A Guide to Apoptosis
Current Cancer Drug Targets Cardiovascular Comorbidities of COPD: When Do they Occur and How are they Managed?
Current Respiratory Medicine Reviews Detection of Fungal Infections Using Radiolabeled Antifungal Agents
Current Drug Targets Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Preoperative Levosimendan. A New Way for Organoprotection
Current Pharmaceutical Design Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design